Drug profile · INN
voxelotor
OXBRYTA
voxelotor (OXBRYTA) is a hemoglobin hba positive modulator. Route of administration: oral. Current US regulatory status: approved.
Drug details — voxelotor
- US status
- approved
- Class
- Blood and blood forming organs (B06)
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.84
Quick answer
voxelotor (OXBRYTA) is a hemoglobin hba positive modulator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hemoglobin HbA positive modulator
Primary target: Hemoglobin HbA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | suspended | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is voxelotor?
voxelotor (OXBRYTA) is a hemoglobin hba positive modulator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for voxelotor?
OXBRYTA is a marketed brand name for voxelotor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of voxelotor?
voxelotor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.